呋塞米能否降低[177Lu]Lu-PSMA放射性配体治疗的肾毒性?
该回顾性研究比较了两个瑞士中心接受至少4周期[177Lu]Lu-PSMA放射性配体治疗的患者,其中CenA在注射后30分钟给予40 mg呋塞米,CenB未给。CenB每周期eGFR显著下降-2 ml/min/1.73m2(CI -2.8/-1.1),p<0.001,而CenA无显著下降(0.3 ml/min/1.73m2,CI -0.6/1.1,p=0.587)。定量SPECT显示呋塞米可能减少肾脏示踪剂蓄积。
要点
- 呋塞米组每周期eGFR无显著下降,未用组显著下降。
- 呋塞米可能减少肾脏对[177Lu]Lu-PSMA的蓄积。
- 呋塞米是否影响疗效需前瞻性研究验证。
核心结论
- 呋塞米可能减少[177Lu]Lu-PSMA治疗后肾脏的示踪剂蓄积,并可能解释CenA中eGFR基本稳定的现象。
研究设计与样本
- 回顾性分析两个瑞士RLT中心接受至少4周期[177Lu]Lu-PSMA治疗的患者,CenA在注射后30分钟给予40 mg呋塞米,CenB未给。
- CenA使用[177Lu]Lu-PSMA-I&T和[177Lu]Lu-PSMA-617,CenB仅使用[177Lu]Lu-PSMA-I&T。
- 采用混合效应模型评估第一队列每周期eGFR和PSA变化,并补充纳入少于4周期患者进行定量SPECT评估肾脏摄取。
主要发现
- CenA纳入24例患者,接受5.4±0.8剂,随访202.0±58天;CenB纳入20例患者,接受5.4±0.9剂,随访210.6±48天。
- CenB每周期eGFR显著下降-2 ml/min/1.73m2(CI -2.8/-1.1),p<0.001;CenA无显著下降,为0.3 ml/min/1.73m2(CI -0.6/1.1),p=0.587。
- 定量分析中,CenB的20例[177Lu]Lu-PSMA-I&T患者平均SUVpeak为7.7±3.1;CenA的16例[177Lu]Lu-PSMA-I&T患者为7.1±3.0,17例[177Lu]Lu-PSMA-617患者为6.2±1.8。
临床怎么用
- 在[177Lu]Lu-PSMA RLT后短期使用呋塞米可能有助于保护肾功能,但需权衡疗效并进一步前瞻性验证。
局限性
- 为回顾性分析,两中心使用的放射性药物不完全相同,肾脏摄取定量样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Impaired renal function after [177Lu]Lu-PSMA radioligand therapy (RLT) is a growing concern as the field moves toward earlier applications. Little is known how renal function could be protected. This study evaluates the impact of furosemide administered shortly after [177Lu]Lu-PSMA RLT, based on long-term follow-up of renal function and quantitative assessment of renal uptake. METHODS: Retrospective analysis of patients treated with a least 4 cycles of [177Lu]Lu-PSMA at two Swiss RLT centers with 40 mg furosemide 30 min after injection (CenA) and without (CenB). CenA used [177Lu]Lu-PSMA-I&T and [177Lu]Lu-PSMA-617, while CenB used only [177Lu]Lu-PSMA-I&T. A mixed-effects model was used to evaluate eGFR and PSA change per cycle in the first cohort. To increase the number for renal uptake of [177Lu]Lu-PSMA-I&T in CenA, supplementary patients with less than 4 cycles were included for quantitative SPECT assessment. RESULTS: In CenA, 24 patients with 5.4±0.8 doses (17 [177Lu]Lu-PSMA-617 / 7 [177Lu]Lu-PSMA-I&T) were followed over 202.0±58 days. In center CenB 20 patients with 5.4±0.9 doses were followed over 210.6±48 days. CenB showed a significant drop in eGFR per cycle of -2 ml/min/1.73m2 (CI − 2.8/−1.1), p < 0.001, while CenA showed no significant decrease per cycle, with 0.3 ml/min/1.73m2 (CI − 0.6/1.1), p = 0.587. For quantitative analysis 20 patients with [177Lu]Lu-PSMA-I&T in CenB had a mean SUVpeak of 7.7±3.1, while 16 patients in CenA with [177Lu]Lu-PSMA-I&T had a mean SUVpeak of 7.1±3.0 and 17 patients with [177Lu]Lu-PSMA-617 had a mean of 6.2±1.8. CONCLUSION: Furosemide may reduce tracer accumulation in the kidneys after [177Lu]Lu-PSMA RLT. This might explain the mostly stable eGFR values observed in CenA, while there was a significant drop in CenB, without furosemide. If diuretics could reduce renal toxicity without impairing efficacy warrants further prospective evaluation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s00259-026-07865-8.
引用
- Pop SG, Strobel K, Heimer J, et al. Could we reduce renal toxicity of [177Lu]Lu-PSMA radioligand therapy with furosemide? Eur J Nucl Med Mol Imaging. 2026. PMID: 41917516. doi:10.1007/s00259-026-07865-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。